Miami, Florida, USA, September 16, 2026
Synergy Spine Solutions® has highlighted new two-year clinical outcomes for its FDA-approved Synergy Disc®, an artificial cervical disc designed for use in cervical spine surgery. The company presented long-term clinical data at the Society for Minimally Invasive Spine Surgery (SMISS) Annual Forum, providing additional evidence on the performance of the motion-preserving spinal implant in patients undergoing cervical disc replacement. According to the company, the two-year results demonstrated improvements in patient-reported outcomes, preservation of cervical motion and favorable clinical performance compared with relevant surgical benchmarks. The presentation adds to the growing body of evidence surrounding the Synergy Disc, which is designed to provide spinal stability while maintaining motion at the treated cervical level.
Two-Year Data Highlight Clinical Outcomes
The clinical findings presented by Synergy Spine Solutions focused on patient outcomes through two years following implantation. Cervical disc replacement is intended to treat symptomatic cervical disc disease while preserving motion at the affected spinal segment, offering an alternative to traditional cervical fusion procedures in appropriately selected patients. The company reported that patients treated with the Synergy Disc experienced sustained improvements in clinical outcomes, including measures of pain and functional status. Patient-reported outcome measures are an important component of evaluating cervical spine implants because they provide information about how treatment affects daily activities, pain levels and overall functional recovery.
The two-year results also included assessment of neurological outcomes and device-related clinical performance. Long-term follow-up is particularly important for artificial disc systems because the objective is not only to relieve symptoms but also to maintain appropriate spinal motion and stability over time. Synergy Spine Solutions said the reported findings reinforce the clinical performance of its cervical disc replacement technology. As with all medical devices, however, individual patient outcomes can vary, and clinical decisions regarding cervical disc replacement depend on factors including anatomy, diagnosis, disease severity and surgeon assessment.
Synergy Disc Designed to Preserve Cervical Motion
Advertisement
The Synergy Disc is an FDA-approved cervical artificial disc developed to replace a damaged or degenerated cervical disc while preserving motion between vertebrae. Conventional anterior cervical discectomy and fusion, or ACDF, removes the diseased disc and uses a fusion construct to stabilize the treated segment. Cervical disc replacement instead seeks to maintain movement at the operated level. Motion preservation is a central concept in artificial disc technology because eliminating motion through fusion may increase biomechanical stress at adjacent spinal segments. Cervical disc replacement systems are therefore designed to reproduce controlled movement while providing sufficient stability.
The Synergy Disc incorporates a mobile-core design intended to allow physiologic movement within the implant while maintaining appropriate alignment. Its clinical evaluation has included patient outcomes, radiographic assessments and device performance over time. The newly highlighted two-year data provide additional follow-up on the durability and clinical behavior of the implant. For spine surgeons, longer-term clinical evidence can help inform decisions about appropriate patients for cervical disc arthroplasty and contribute to the broader scientific understanding of motion-preserving spine surgery.
Clinical Evidence Supports Minimally Invasive Spine Care
The presentation at the SMISS Annual Forum places the Synergy Disc within the broader development of minimally invasive and motion-preserving approaches to spinal surgery. The field continues to explore techniques and implant technologies that can reduce surgical morbidity, improve recovery and preserve normal or near-normal spinal biomechanics. Synergy Spine Solutions said the two-year clinical outcomes demonstrate the potential of its technology to provide sustained patient benefits while maintaining cervical segment motion. The company also emphasized the importance of long-term clinical evidence in evaluating artificial disc replacement technologies.
The latest findings add to the clinical evidence supporting the FDA-approved Synergy Disc and its use in appropriately selected patients. Continued follow-up will be important for understanding longer-term implant performance, including motion preservation, adjacent-segment health, revision rates and other clinical outcomes. The development reflects continued innovation in spinal implants and cervical disc replacement technology, as medical-device companies seek to provide alternatives to fusion for eligible patients with cervical disc disease. Further clinical research and real-world experience will help establish the longer-term role of the Synergy Disc in modern spine surgery.
Source: Synergy Spine press release
